

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINOPHARM GROUP CO. LTD.*
國藥控股股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT
CHANGE OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) announces that due to change in responsibilities, Mr. Ma Wanjun (the “**Mr. Ma**”) has tendered his resignation from his positions as secretary to the Board, joint company secretary and authorised representative of the Company with effect from 28 October 2016. Mr. Ma has confirmed that there is no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders and creditors of the Company. On the same day, Mr. Liu Yong (“**Mr. Liu**”) has been appointed by the Board as the new secretary to the Board, joint company secretary and authorised representative of the Company, with effect from 28 October 2016.

The Board also announces that, the Company has applied for, and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Listing Rules**”) for a period of three years from the date of appointment of Mr. Liu in respect of the appointment of Mr. Liu as the joint company secretary of the Company, on the condition that Mr. Liu will be assisted by Dr. Liu Wei (“**Dr. Liu**”) to acquire the relevant experience within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the joint company secretary of the Company. Dr. Liu has PRC lawyer qualification and is qualified to practice as a solicitor in Hong Kong and England. Dr. Liu has served as the joint company secretary of the Company since 24 August 2011.

Mr. Ma has confirmed that there is no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders and creditors of the Company. The Board would like to take this opportunity to express its gratitude to Mr. Ma for his contribution to the Company during his tenure as the secretary to the Board, joint company secretary and authorised representative of the Company, and to express its warm welcome to Mr. Liu for his appointment as the new secretary to the Board, joint company secretary and authorised representative of the Company.

BIOGRAPHICAL DETAILS

Mr. Liu Yong, aged 47, joined the Group in January 2003. He currently serves as vice president and the chief legal advisor of the Company. He has over 23 years of working experience, among which, more than 20 years is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelor's degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a master's degree in business administration from Fudan University in January 2000, and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Corporation and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. from January 2003 to November 2009. Mr. Liu started to serve as the vice president of the Company since January 2009, and started to serve as the chief legal advisor of the Company since January 2014. Mr. Liu now concurrently serves as the chairman of Sinopharm Holding Beijing Tianxingpuxin BioMed Co., Ltd., Sinopharm Holding Beijing Co., Ltd., Sinopharm Holding Beijing Kangchen Bio-medicine Co., Ltd., Sinopharm Holding Guizhou Co., Ltd., Sinopharm Holding Yunnan Co., Ltd., Sinopharm Medicine Holding Beijing Huahong Co., Ltd., Sinopharm Online Co., Ltd. and China National Medicines Co., Ltd..

By order of the Board of
Sinopharm Group Co. Ltd.
Wei Yulin
Chairman

Shanghai, the PRC
28 October 2016

As at the date of this announcement, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*